Cerebrolysin

Based on years of clinical experience, post-marketing surveillance data, safety data from double-blind, placebo-controlled clinical trials, and EVER's pharmacovigilance database, Cerebrolysin® has demonstrated excellent clinical safety.

According to the European Medicines Agency (EMA) classification, Cerebrolysin® belongs to the SAFE category of drugs. Adverse reactions reported are generally transient and mild.

Please note that proper administration procedures are crucial.